Zydus Wellness Q2 Results Live : Zydus Wellness declared their Q2 results on 11 Nov, 2024, showcasing impressive financial growth. The company’s topline increased by 12.05% year-over-year, while profit surged by an astonishing 254.24%. This significant rise in profit reflects the company’s strong operational performance and market positioning.
However, when comparing the results to the previous quarter, Zydus Wellness experienced a decline in both revenue and profit, with revenue down by 41.39% and profit decreasing by 85.85%. This quarterly comparison highlights the volatility in the company’s performance and the need for sustained growth.
The company’s selling, general, and administrative expenses saw a noteworthy decline of 37.07% quarter-over-quarter but increased by 16.77% year-over-year. This indicates a focused effort to manage costs effectively in the current economic environment.
Operating income also faced a considerable drop, down by 90.21% compared to the previous quarter, yet it recorded a year-over-year increase of 36.11%. This contrasting performance suggests that while the company is facing short-term challenges, there are underlying strengths driving year-over-year growth.
Earnings per share (EPS) for Q2 stands at ₹2.46, reflecting a robust increase of 164.89% year-over-year. This performance metric is a positive indicator for investors looking at the company’s profitability.
In terms of market performance, Zydus Wellness has delivered a -1.18% return in the last week, but a more encouraging 14.41% return over the past six months and a 14.78% return year-to-date. These figures demonstrate the stock’s resilience amid fluctuating market conditions.
Currently, Zydus Wellness holds a market capitalization of ₹12,278.46 crore with a 52-week high of ₹2,484 and a low of ₹1,440.15. This range highlights the volatility and potential for growth in the company’s stock value.
As of 12 Nov, 2024, out of five analysts covering Zydus Wellness, two have given a ‘Hold’ rating while three analysts have recommended a ‘Buy’. The consensus recommendation points towards a positive outlook for the company, indicating investor confidence in its future performance.
Zydus Wellness Financials
| Period | Q2 | Q1 | Q-o-Q Growth | Q2 | Y-o-Y Growth |
|---|---|---|---|---|---|
| Total Revenue | 492.9 | 841 | -41.39% | 439.9 | +12.05% |
| Selling/ General/ Admin Expenses Total | 115.6 | 183.7 | -37.07% | 99 | +16.77% |
| Depreciation/ Amortization | 4.9 | 5.1 | -3.92% | 5.8 | -15.52% |
| Total Operating Expense | 478.2 | 690.9 | -30.79% | 429.1 | +11.44% |
| Operating Income | 14.7 | 150.1 | -90.21% | 10.8 | +36.11% |
| Net Income Before Taxes | 23.7 | 151.6 | -84.37% | 8.6 | +175.58% |
| Net Income | 20.9 | 147.7 | -85.85% | 5.9 | +254.24% |
| Diluted Normalized EPS | 2.46 | 23.21 | -89.39% | 0.93 | +164.89% |
